COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
Aridis Pharmaceuticals Inc
Positive efficacy data reported from preclinical trial of AR-711 for non-hospitalized mild-to-moderate COVID-19 patients
Phase 1/2 study of AR-711 is expected to be launched in 1H 2021
Pfizer Inc.
BNT162 Vaccine program
BNT162 program includes 4 vaccine candidates; BNT162b2 has been advanced into phase global trial.

-- The EMA and Health Canada have already begun rolling review of BNT162b2.

-- On Nov.9, interim results from phase 3 trial reported which showed over 90% efficacy.

-- Announced a vaccine efficacy rate of 95% on Nov.18

-- Filed for Emergency Use Authorization to the FDA on Nov.20
Emergency use approval expected by mid-December
BioNTech SE
RedHill Biopharma Ltd.
FDA has cleared Phase 2/3 study of orally administered RHB-107 in patients with symptomatic COVID-19 who do not require hospitalization
Initiation of phase 2/3 trial
BioLineRx Ltd.
Motixafortide for ARDS secondary to COVID-19
Phase I trial of Motixafortide in patients suffering from acute respiratory distress syndrome (ARDS) secondary to COVID-19
Results of preliminary analysis expected in H1 2021
Johnson & Johnson
Ad26.COV2.S Vaccine
Phase 3 trial of a two-dose regimen of Ad26.COV2.S, dubbed ENSEMBLE 2
UK National Institute for Health Research (NIHR)
Moderna, Inc
mRNA-1273 Vaccine
Phase III study, dubbed COVE, completed enrollment on Oct.22.

Interim data reported on Nov.16, revealed 94.5% efficacy
Seek Emergency Use Authorization from the FDA and other regulatory authorities
Biological E. Limited
COVID-19 Vaccine Candidate
Phase I/II trial
The results of phase I/II trial are expected to be available by February 2021
Dynavax Technologies Corporation (DVAX), and Baylor College of Medicine
Q BioMed Inc.
MAN-19 to treat complications caused by COVID-19
Phase 1 trial
Phase 1 trial to begin patient enrollment in February 2021

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Guitar Center Inc., a retailer of musical instruments, lessons, repairs and rentals, has filed for Chapter 11 bankruptcy reorganization, aiming to significantly reduce its debt and continue its business amid ongoing struggles following the coronavirus pandemic. The company, which operates nearly 300 stores across the U.S., expects to complete the process before the end of this year. Amazon is offering new "Spoiler Free" ways to keep gifts a surprise, as well as to track, receive and pick up orders this holiday season. According to the company, the new features would help customers to face the challenge of keeping those special gifts under wraps as many families are opting to stay home amid the coronavirus pandemic. AstraZeneca Plc and Oxford University's coronavirus vaccine candidate AZD1222 is found to be 70 percent effective on average against Covid-19, according to the British pharmaceutical giant. AstraZeneca plans to immediately prepare regulatory submission of the data to worldwide authorities for conditional or early approval. The company will also ask for an Emergency Use Listing from the WHO.